PMID- 32092619 OWN - NLM STAT- MEDLINE DCOM- 20200324 LR - 20200324 IS - 1532-1967 (Electronic) IS - 0305-7372 (Linking) VI - 85 DP - 2020 Apr TI - An evidence-based guideline on the application of molecular testing in the diagnosis, prediction of prognosis, and selection of therapy in non-GIST soft tissue sarcomas. PG - 101987 LID - S0305-7372(20)30025-6 [pii] LID - 10.1016/j.ctrv.2020.101987 [doi] AB - AIMS: To make recommendations on the indications for molecular testing regarding the diagnosis, prediction of prognosis, and treatment selection in adult patients with s oft tissue sarcomas (STS) excluding gastrointestinal stromal tumour. MATERIALS AND METHODS: This guideline was developed by the Cancer Care Ontario's Program in Evidence-Based Care (PEBC) and the Sarcoma Disease Site Group (DSG). The medline, embase, and Cochrane Library databases, main guideline websites, abstracts of relevant annual meetings, and PROSPERO databases were searched (January 2005 to October 2016). Internal and external reviews were conducted, with final approval by the PEBC and the Sarcoma DSG. RESULTS: Based on the available evidence, we made three S trong Recommendations, 14 Recommendations, 9 Qualified Statements, and seven No Recommendations. The three Strong Recommendations include: i) MDM2 amplification by fluorescence in situ hybridization (FISH) is recommended as a sensitive and specific test to differentiate patients with atypical lipomatous tumour/well-differentiated liposarcoma, or dedifferentiated liposarcoma from lipoma or other STS in the differential diagnosis; ii) SS18 (SYT) break-apart by FISH or SS18-SSX (SYT-SSX) fusion by reverse transcription-polymerase chain reaction is recommended as a sensitive and specific test to differentiate patients with synovial sarcoma from other sarcomas; iii) CTNNB1 S45F mutation by polymerase chain reaction is recommended as a prognostic factor for poor recurrence-free survival in patients with desmoid tumours. CONCLUSION: This guideline may serve as a framework for the thoughtful implementation of molecular studies at cancer centres and other jurisdictions. Some of the recommendations may need to be updated when new evidence appears in the future. CI - Copyright (c) 2020 Elsevier Ltd. All rights reserved. FAU - Yao, Xiaomei AU - Yao X AD - Program in Evidence-Based Care, Cancer Care Ontario, Department of Oncology, McMaster University, Hamilton, Ontario, Canada. Electronic address: yaoxia@mcmaster.ca. FAU - Ghert, Michelle AU - Ghert M AD - Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. Electronic address: ghertm@mcmaster.ca. FAU - Dickson, Brendan C AU - Dickson BC AD - Division of Orthopedic Surgery, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada. Electronic address: Brendan.Dickson@sinaihealthsystem.ca. FAU - Popovic, Snezana AU - Popovic S AD - Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario. Electronic address: popovics@hhsc.ca. FAU - Purgina, Bibianna M AU - Purgina BM AD - Department of Pathology and Laboratory Medicine, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada. Electronic address: bpurgina@toh.ca. FAU - Verma, Shailendra AU - Verma S AD - Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada. Electronic address: sverma@toh.ca. FAU - Werier, Joel AU - Werier J AD - Division of Orthopedic Surgery, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada. Electronic address: jwerier@toh.ca. FAU - Kandel, Rita A AU - Kandel RA AD - Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. Electronic address: ccopgi@mcmaster.ca. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20200214 PL - Netherlands TA - Cancer Treat Rev JT - Cancer treatment reviews JID - 7502030 RN - 0 (Biomarkers, Tumor) RN - 0 (Oncogene Proteins, Fusion) SB - IM MH - Biomarkers, Tumor/*genetics MH - Evidence-Based Medicine MH - Female MH - Gastrointestinal Stromal Tumors/diagnosis/genetics MH - Genetic Testing MH - Humans MH - Male MH - Oncogene Proteins, Fusion/*genetics MH - Ontario MH - *Practice Guidelines as Topic MH - Prognosis MH - Sarcoma/diagnosis/*genetics/therapy MH - Sensitivity and Specificity MH - Soft Tissue Neoplasms/diagnosis/*genetics/therapy OTO - NOTNLM OT - Clinical practice guideline, OT - Diagnosis OT - Prognosis OT - Soft tissue sarcoma OT - Treatment selection COIS- Declaration of Competing Interest BCD has received molecular test kits (free of charge) from Illumina, and MG has declared that she received more than $5,000 in 2017 to act in a consulting capacity from Wright Medical and Kuros Biosciences. The other authors have declared no conflicts of interest. EDAT- 2020/02/25 06:00 MHDA- 2020/03/25 06:00 CRDT- 2020/02/25 06:00 PHST- 2018/07/03 00:00 [received] PHST- 2020/02/10 00:00 [revised] PHST- 2020/02/11 00:00 [accepted] PHST- 2020/02/25 06:00 [pubmed] PHST- 2020/03/25 06:00 [medline] PHST- 2020/02/25 06:00 [entrez] AID - S0305-7372(20)30025-6 [pii] AID - 10.1016/j.ctrv.2020.101987 [doi] PST - ppublish SO - Cancer Treat Rev. 2020 Apr;85:101987. doi: 10.1016/j.ctrv.2020.101987. Epub 2020 Feb 14.